This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

TD Cowen Keeps Their Hold Rating on GlaxoSmithKline (GSK)

Tipranks - Tipranks - Fri Jun 12, 11:56AM CDT

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline, with a price target of $70.00.

Introducing TipRanks MCP for Agents

According to TipRanks, Scala is a 4-star analyst with an average return of 10.2% and a 62.81% success rate. Scala covers the Healthcare sector, focusing on stocks such as Sanofi, Eli Lilly & Co, and GlaxoSmithKline.

GlaxoSmithKline has an analyst consensus of Moderate Buy, with a price target consensus of $63.70.

See today’s best-performing stocks on TipRanks >>

Based on GlaxoSmithKline’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $7.63 billion and a net profit of $1.74 billion. In comparison, last year the company earned a revenue of $7.52 billion and had a net profit of $1.62 billion

Read More on GSK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).